Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EBIT (2016 - 2025)

Tandem Diabetes Care's EBIT history spans 13 years, with the latest figure at $8.3 million for Q4 2025.

  • For Q4 2025, EBIT rose 1527.54% year-over-year to $8.3 million; the TTM value through Dec 2025 reached -$187.3 million, down 88.91%, while the annual FY2025 figure was -$187.3 million, 88.91% down from the prior year.
  • EBIT reached $8.3 million in Q4 2025 per TNDM's latest filing, up from -$22.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $12.7 million in Q4 2021 to a low of -$127.8 million in Q1 2023.
  • Average EBIT over 5 years is -$29.5 million, with a median of -$24.5 million recorded in 2024.
  • Peak YoY movement for EBIT: plummeted 733.34% in 2023, then skyrocketed 1527.54% in 2025.
  • A 5-year view of EBIT shows it stood at $12.7 million in 2021, then crashed by 239.56% to -$17.8 million in 2022, then tumbled by 97.22% to -$35.1 million in 2023, then skyrocketed by 98.34% to -$581000.0 in 2024, then surged by 1527.54% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's EBIT are $8.3 million (Q4 2025), -$22.9 million (Q3 2025), and -$51.8 million (Q2 2025).